News

A treatment to reduce the activation of the immune complement system didn’t increase the effectiveness of red blood cell transfusions in people with severe cold agglutinin disease (CAD) and other complement-mediated autoimmune hemolytic anemia (CM-AIHA). That’s according to a small, proof-of-concept Phase 2 clinical trial (EudraCT2012-003710-13) that found…

A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…

The rare case of a young woman with cold agglutinin disease (CAD) secondary to chickenpox, also known as varicella, was described in a recent report in India. While corticosteroids, a type of steroid, are usually not recommended for CAD secondary to an infection, the rapid and sustained red blood…

Enrollment is underway in a Phase 3 clinical trial testing the investigational therapy pegcetacoplan in adults with primary cold agglutinin disease (CAD), according to a corporate update from the treatment’s developer, Apellis Pharmaceuticals. The trial, called CASCADE (NCT05096403), is enrolling up to 57 patients, 18…

Signs of cold agglutinin disease (CAD) — later found to have been triggered by a previous COVID-19 infection — were detected during heart surgery in a man in Turkey, a case study showed. The case adds to several others reporting developing CAD following COVID-19 disease. Despite being rare,…

Splenectomy, or the surgical removal of the spleen, significantly reduced unmanageable red blood cell destruction in a man with primary cold agglutinin disease (CAD), a study showed. While this approach is usually considered to be ineffective in CAD patients, this case report adds to other studies where  CAD was successfully…

Fetal complications are about four times more common in pregnant women with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), than in those without the autoimmune condition, according to a small study. Still, maternal complications occurred at similar rates, and most were directly linked to AIHA relapses, or…

Note: This story was updated Jan. 30, 2023,  to correct that the CARDINAL trial did not include a placebo group. The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of…

Special considerations should be taken when preparing a blood transfusion for someone with cold agglutinin disease (CAD), a recent study indicates. The study, “Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies,” was published…

A new case study reports the rare co-occurrence of cold agglutinin disease (CAD) and blood cancer in a man in Iran. The patient, 56, who had been diagnosed with myelodysplastic syndrome (MDS), an umbrella term for a group of rare blood cancers, was found to also have CAD…